» Articles » PMID: 33382852

Risk Factors of Papillary Thyroid Microcarcinoma That Predispose Patients to Local Recurrence

Overview
Journal PLoS One
Date 2020 Dec 31
PMID 33382852
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Currently, less aggressive treatment or even active surveillance of papillary thyroid microcarcinoma (PTMC) is widely accepted and recommended as a therapeutic management option. However, there are some concerns about these approaches. We investigated whether there are any demographic, clinical and ultrasound characteristics of PTMC patients that are easy to obtain and clinically available before surgery to help clinicians make proper therapeutic decisions.

Methods: We performed a retrospective chart review of 5,021 patients with thyroid tumors surgically treated in one center in 2008-2018. Finally, 182 (3.62%) PTMC patients were selected (158 (86.8%) females and 24 (13.2%) males, mean age 48.8±15.4 years). We analyzed the disease-free survival (DFS) time of the PTMC patients according to demographic and histopathological parameters. Univariate and multivariate logistic regression analyses were used to assess the relationships of demographic, clinical and ultrasound characteristics with aggressive histopathological features.

Results: Age ≥55 years, hypoechogenicity, microcalcifications, irregular tumor shape, smooth margins and high vascularity significantly increased the risk for minimal extrathyroidal extension (minETE), lymph node metastasis (LNM), and capsular and vascular invasion (p<0.0001). Multivariate logistic regression analysis demonstrated a statistically significant risk of LNM (OR = 5.98, 95% CI: 2.32-15.38, p = 0.0002) and trends toward significantly higher rates of minETE and capsular and vascular invasion (OR = 2.24, 95% CI: 0.97-5.19, p = 0.056) in patients ≥55 years than in their younger counterparts. The DFS time was significantly shorter in patients ≥55 years (p = 0.015), patients with minETE and capsular and vascular invasion (p = 0.001 for all), patients with tumor size >5 mm (p = 0.021), and patients with LNM (p = 0.002).

Conclusions: The absence of microcalcifications, irregular tumor shape, blunt margins, hypoechogenicity and high vascularity in PTMC patients below 55 years and with tumor diameters below 5 mm may allow clinicians to select individuals with a low risk of local recurrence so that they can receive less aggressive management.

Citing Articles

Correlation of pN Stage and Hypoechogenicity with Tumour Encapsulation and Vascular Invasion in Thyroid Cancer (TC): A Comprehensive Analysis and Clinical Outcomes.

Jurkiewicz K, Miciak M, Biernat S, Wojtczak B, Kaliszewski K Cancers (Basel). 2024; 16(11).

PMID: 38893139 PMC: 11171334. DOI: 10.3390/cancers16112019.


Application of ultrasound elastography and radiomic for predicting central cervical lymph node metastasis in papillary thyroid microcarcinoma.

Wu L, Zhou Y, Li L, Ma W, Deng H, Ye X Front Oncol. 2024; 14:1354288.

PMID: 38800382 PMC: 11116610. DOI: 10.3389/fonc.2024.1354288.


Frequency of Thyroid Microcarcinoma in Patients Who Underwent Total Thyroidectomy with Benign Indication-A 5-Year Retrospective Review.

Magra V, Boulogeorgou K, Paschou E, Sevva C, Manaki V, Mpotani I Medicina (Kaunas). 2024; 60(3).

PMID: 38541194 PMC: 10972442. DOI: 10.3390/medicina60030468.


Papillary Thyroid Microcarcinoma: Differences between Lesions in Incidental and Nonincidental Settings-Considerations on These Clinical Entities and Personal Experience.

Lucandri G, Fiori G, Falbo F, Pende V, Farina M, Mazzocchi P Curr Oncol. 2024; 31(2):941-951.

PMID: 38392064 PMC: 10888372. DOI: 10.3390/curroncol31020070.


Clinical and molecular features of progressive papillary thyroid microcarcinoma.

Wang Z, Ji X, Zhang H, Sun W Int J Surg. 2024; 110(4):2313-2322.

PMID: 38241301 PMC: 11019976. DOI: 10.1097/JS9.0000000000001117.


References
1.
Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Uruno T . Occult papillary thyroid carcinoma: diagnostic and clinical implications in the era of routine ultrasonography. World J Surg. 2008; 32(9):1955-60. DOI: 10.1007/s00268-008-9614-9. View

2.
Shawky M, Proctor I, Kurzawinski T, Abdel-Aziz T . Papillary thyroid microcarcinoma presenting as a metastasis to the brain. Ann R Coll Surg Engl. 2020; 102(5):e107-e110. PMC: 7374782. DOI: 10.1308/rcsann.2020.0041. View

3.
Miyauchi A . Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. World J Surg. 2016; 40(3):516-22. PMC: 4746213. DOI: 10.1007/s00268-015-3392-y. View

4.
Yamashita G, Kondo T, Okimura A, Nakatsugawa M, Hirano H, Takeda A . Occult Papillary Thyroid Carcinoma without Detection of the Primary Tumor on Preoperative Ultrasonography or Postoperative Pathological Examination: A Case Report. Case Rep Oncol. 2020; 13(1):105-112. PMC: 7098349. DOI: 10.1159/000505831. View

5.
Takano T . Natural history of thyroid cancer [Review]. Endocr J. 2017; 64(3):237-244. DOI: 10.1507/endocrj.EJ17-0026. View